TABLE 2.
Change From Baseline in VAS Scores (0–100) and OSDI
| NOV03 QID–Saline* | NOV03 BID–Saline* | |
| Point Estimate of Mean Difference (95% CI); P | Point Estimate of Mean Difference (95% CI); P | |
| Dryness Score | ||
| Week 2 | −11.8 (−17.6 to −6.0); <0.001 | −7.3 (−13.2 to −1.5); 0.015 |
| Week 4 | −9.1 (−1.91 to −0.65); 0.005 | −5.3 (−11.6 to 1.07); 0.103 |
| Week 8 | −11.8 (−18.7 to −5.0); <0.001 | −10.7 (−17.6 to −3.8); 0.002 |
| Frequency of dryness | ||
| Week 2 | −10.6 (−17.0 to −4.2); 0.001 | −3.9 (−10.3 to 2.6); 0.237 |
| Week 4 | −8.8 (−15.4 to −2.2); 0.009 | −4.2 (−10.8 to 2.4); 0.216 |
| Week 8 | −12.9 (−20.3 to −5.5); <0.001 | −11.6 (−19.1 to −4.1); 0.002 |
| Awareness of eye symptoms | ||
| Week 2 | −11.0 (−17.5 to −4.6); <0.001 | −5.1 (−11.5 to 1.4); 0.124 |
| Week 4 | −11.4 (−18.2 to −4.6); 0.001 | −7.1 (−13.9 to −0.3); 0.040 |
| Week 8 | −13.1 (−20.5 to −5.6); <0.001 | −12.6 (−20.1 to −5.1); 0.001 |
| Sticky feeling | ||
| Week 2 | −9.7 (−15.2 to −4.1); <0.001 | −6.0 (−11.6 to −0.4); 0.035 |
| Week 4 | −3.3 (−9.0 to 2.4); 0.259 | −0.7 (−6.5 to 5.0); 0.805 |
| Week 8 | −3.6 (−9.7 to 2.5); 0.246 | −3.0 (−9.2 to 3.2); 0.338 |
| Burning/stinging | ||
| Week 2 | −8.00 (−14.1 to −1.8); 0.011 | −6.7 (−12.9 to −0.5); 0.034 |
| Week 4 | −5.6 (−12.1 to 0.9); 0.092 | −1.0 (−7.5 to 5.6); 0.771 |
| Week 8 | −10.7 (−16.7 to −4.6); <0.001 | −6.4 (−12.6 to −0.3); 0.04 |
| Foreign body sensation | ||
| Week 2 | −6.6 (−12.6 to −0.7); 0.029 | −6.2 (−12.2 to 0.3); 0.041 |
| Week 4 | −8.3 (−14.4 to −2.3); 0.007 | −2.3 (−8.4 to 3.8); 0.453 |
| Week 8 | −4.0 (−10.2 to 2.3); 0.213 | −3.0 (−9.3 to 3.3); 0.345 |
| Itching | ||
| Week 2 | −8.7 (−14.7 to −2.8); 0.004 | −6.9 (−12.9 to −0.9); 0.025 |
| Week 4 | −7.4 (−13.7 to −1.1); 0.022 | −3.0 (−9.3 to 3.3); 0.353 |
| Week 8 | −5.1 (−11.1 to 1.0); 0.103 | −4.3 (−10.4 to 1.8); 0.168 |
| Blurred vision | ||
| Week 2 | −2.6 (−9.0 to 3.8); 0.423 | −2.3 (−8.8 to 4.1); 0.479 |
| Week 4 | −3.6 (−10.4 to 3.2); 0.294 | −1.9 (−8.7 to 5.0); 0.592 |
| Week 8 | −3.7 (−10.8 to 3.3); 0.301 | −3.4 (−10.5 to 3.8); 0.352 |
| Pain | ||
| Week 2 | −3.6 (−9.7 to 2.5); 0.246 | −0.3 (−6.5 to 5.8); 0.916 |
| Week 4 | −0.4 (−5.8 to 4.9); 0.872 | 1.3 (−4.1 to 6.7); 0.634 |
| Week 8 | −7.8 (−13.3 to −2.4); 0.005 | −4.4 (−10.0 to 1.1); 0.116 |
| Sensitivity to light | ||
| Week 2 | −3.6 (−9.8 to 2.6); 0.250 | −4.4 (−10.6 to 1.8); 0.167 |
| Week 4 | −1.7 (−8.5 to 5.2); 0.634 | −2.3 (−9.2 to 4.6); 0.511 |
| Week 8 | −8.1 (−15.4 to −0.9); 0.028 | −6.6 (−13.9 to 0.74); 0.078 |
| OSDI | ||
| Week 2 | −4.2 (−8.32 to −0.04); 0.048 | −1.8 (−5.91 to 2.42); 0.410 |
| Week 4 | −4.7 (−9.37 to −0.10); 0.045 | −1.2 (−5.86 to 3.45); 0.610 |
| Week 8 | −4.3 (−9.24 to 0.62); 0.087 | −3.0 (−7.98 to 1.97); 0.235 |
*
For mean treatment difference in CFB.